New hope for tough myeloma: drug combo shows promise in early trial
NCT ID NCT05560399
First seen Jan 06, 2026 · Last updated May 20, 2026 · Updated 21 times
Summary
This study tests a new three-drug combination (iberdomide, elotuzumab, and dexamethasone) in people whose multiple myeloma has returned or stopped responding to treatment. The goal is to see if the combination is safe and can shrink tumors. About 37 adults with this blood cancer will take part. The approach aims to control the disease, not cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Icahn School of Medicine
New York, New York, 10029, United States
Conditions
Explore the condition pages connected to this study.